- Opening keynote from Tim Haines, Executive Partner at Abingworth, to provide a review of the life science investment landscape
- Expected to welcome c900 delegates [SB1] spanning early-stage life science R&D, investors, pharma, academics, charities, government and industry service providers
- Two-day life science conference taking place 1st-2nd April in London, UK
Oxford and London, UK, 05 March 2025: OBN (UK) Ltd., the membership organisation whose mission is to catalyse success in the life science industry, is pleased to invite R&D companies, professionals and investors from across the life science and pharma industries to attend BioTrinity 2025 on 1st-2nd April in London, UK.
BioTrinity is OBN’s flagship life science conference, designed to unite key industry stakeholders, foster collaboration and catalyse growth. The conference welcomes delegates from early and emerging life science R&D companies, investors, academics, large pharma, government and a broad range of industry service providers, as well as key life science clusters across Europe, the US, Asia and beyond.
Following a sold-out 2024 event, BioTrinity will once again be taking place at 133 Houndsditch, with approximately 900 professionals expected to attend. The two-day event will feature a dual track of scientific talks, showcasing innovative companies at or around the Series A stage across 14 different therapy areas. Alongside this, a dedicated business and investment track will provide a platform for industry leaders to discuss important topics including fundraising, leadership, how to effectively approach M&A, collaborating for success and the evolving regulatory landscape.
In addition to the presentation tracks running throughout the event, BioTrinity 2025 will also offer:
- Sponsors’ exhibition hall, featuring a broad selection of life science service providers
- Networking events
- Dedicated partnering system and space for private 1:1 partnering meetings
- Academic poster presentation session
“It is fantastic to see BioTrinity continuing to grow year on year, cementing its place as a leading life science event in the UK.” Said Stuart Rose, CEO of OBN. He continued: “Building on the success of the 2024 event, which saw us move to a new venue and significantly expand our offering and headcount, we look forward to welcoming close to 900 attendees to BioTrinity 2025 and helping to expand networks, forge new partnerships and accelerate scientific discovery across the life sciences. I would like to say a big thank you to our hard-working team, and of course to all our partners and sponsors for making this event possible.”
To access the full event programme of speakers and sessions and to register, please visit: https://obn.glueup.com/event/biotrinity-2025-109682/.
Follow OBN on LinkedIn (OBN UK) for updates on this event, and more.
